Drug intelligence / Profile preview

9B05

Development stage: Preclinical
Lead developer: 9Bio Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

9B05 is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by 9Bio Therapeutics. It is designed to target two distinct tumor antigens: one associated with cancer stemness, chemotherapy resistance, and metastasis, and a second novel antigen linked to metastatic progression in colorectal, gastric, and breast cancers. By dual-targeting these antigens, 9B05 aims to overcome tumor heterogeneity and resistance mechanisms. The drug is currently being evaluated for the treatment of breast cancer, colorectal cancer, gastric cancer, and liver metastatic disease.

Beyond the preview

Go deeper on 9B05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9B05.

Explore the full profile